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See Article, pages 799–808An interesting study by Gomez-Hurtado et al. in this month’s
issue of the Journal of Hepatology highlights new effects of
norﬂoxacin on gut-associated lymphatic tissue (GALT) and trans-
location of bacterial products in murine models of cirrhosis [1].
Norﬂoxacin, launched in 1980, was the ﬁrst commercially avail-
able ﬂuoroquinolone. The beneﬁcial role of norﬂoxacin in
cirrhosis has been clearly demonstrated in several studies. Oral
norﬂoxacin administration (400 mg/day) improves the circula-
tory derangement observed in cirrhotic patients, which is charac-
terized by high cardiac output and low systemic vascular
resistance [2,3]. Norﬂoxacin decreases the recurrence of sponta-
neous bacterial peritonitis (SBP) from 70% to 20% after a ﬁrst
episode (secondary prophylaxis) [4]. Norﬂoxacin in patients with
low protein ascitic levels (<1.5 g/dl) and advanced cirrhosis
(Child-Pugh score P9 points with serum bilirubin level P3 mg/dl
or impaired renal function (serum creatinine level P1.2 mg/dl,
blood urea nitrogen level P25 mg/dl, or serum sodium level
6130 mEq/L)) without prior SBP episode reduces the probability
of SBP (primary prophylaxis) and hepatorenal syndrome (HRS)
and improves 3-month survival [5].
The justiﬁcation for norﬂoxacin administration in cirrhosis is
based on its antibiotic effects on gut microbiota. Indeed, cirrhosis
is associated with a pro-inﬂammatory process characterized by
increased circulating cytokines (tumour necrosis factor (TNF)-a
and interleukin (IL)-6) and a primed state of peripheral blood
mononuclear cells [6,7]. Bacterial translocation (BT) seems to
be the main trigger of this systemic inﬂammation. Viable bacteria
have been frequently isolated from mesenteric lymph nodes, and
bacterial products, such as lipopolysaccharides (LPS) and bacte-
rial DNA, have been detected in the blood of patients with
decompensated cirrhosis [8–10]. Increased BT is permitted by
increased intestinal permeability which is partially due to altera-
tions in tight junction (TJ) proteins that are present in the
advanced stages of cirrhosis [11]. Intestinal bacterial overgrowth
and dysbiosis (qualitative changes in the microbiome) observed
in cirrhosis also contribute to BT [12,13]. On the other hand,Journal of Hepatology 20
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pen access under CC BY-NC-ND license.gut inﬂammation observed in cirrhosis and intestinal macro-
phages producing nitric oxide and IL-6 might disrupt the intesti-
nal barrier and contribute to bacterial translocation, creating a
vicious cycle [14]. Several years ago, Albillos et al. demonstrated
that administration of norﬂoxacin in order to achieve selective
intestinal gut decontamination reduces plasma levels of TNF-a,
IL-6, and other surrogate markers of BT (LPS-binding protein
and soluble CD14) in cirrhotic patients with ascites [3].
Prolonged antibiotic administration leads to the rapid
emergence of resistant bacteria. Epidemiological studies have
clearly demonstrated that long-term norﬂoxacin administration
increases the risk of infections caused by quinolone-resistant, tri-
methoprim-sulfamethoxazole-resistant and extended-spectrum
b-lactamase (ESBL)-producing strains in cirrhosis [15,16]. This
has a major impact on the natural outcome of cirrhosis because
infections with multi-resistant bacteria are associated with
higher mortality rates than those with susceptible bacteria.
Despite high rates of quinolone-resistant bacteria reported in
Spain during the same period of a primary prophylaxis trial,
norﬂoxacin maintained its efﬁcacy in SBP and HRS prevention
suggesting a potential non-antibiotic effect [5].
Norﬂoxacin exerts anti-bacterial effects by inhibiting bacterial
DNA gyrase and topoisomerase IV [17]. Besides their anti-bacte-
rial effects, quinolones have immunomodulatory activities
(inhibitory effects on cytokines, chemokines, and other compo-
nents of the immune system) through incompletely understood
mechanisms [18]. These mechanisms include effects on intracel-
lular cyclic AMP and phosphodiesterases, several transcription
factors such as NFjB, AP1, and NFAT, and topoisomerase II. In
cirrhotic patients receiving oral norﬂoxacin, these effects are sug-
gested by a study demonstrating an inverse correlation between
serum norﬂoxacin and pro-inﬂammatory cytokine (TNF-a, IL-12,
and interferon (IFN)-c) concentrations [19]. Moreover, norﬂoxa-
cin-induced down-regulation of inﬂammation seems to be due
to an induction of IL-10 and heme oxygenase (HO)-1 [20].
In the current issue of the Journal of Hepatology,
Gomez-Hurtado et al. reinforce the concept that IL-10 is involved
in the beneﬁcial effects of norﬂoxacin in cirrhosis through the use
of IL-10-deﬁcient mice [1]. Inmurinemodels of cirrhosis (CCl4 and
bile duct ligation models), the administration of norﬂoxacin was
associated with a reduction of serum and mesenteric lymph node14 vol. 61 j 725–726
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(MLN) LPS concentrations, gut permeability to LPS, and increased
expression of TJ proteins (TJP-1 and occludin) responsible for gut
barrier integrity. In IL-10-deﬁcient mice, the effects of norﬂoxacin
were not observed and supplementation of IL-10 to these mice
restored norﬂoxacin action, elegantly supporting an IL-10-depen-
dent mechanism. In in vitro experiments, norﬂoxacin directly
inhibited LPS-induced TNF-a production by intestinal mononu-
clear cells through an IL-10-dependent pathway. On the other
hand, norﬂoxacin reduced spontaneous and induced BT in wild-
type and IL-10-deﬁcient mice. Taken together, these data suggest
that norﬂoxacin exerts its effects through a reduction of bacterial
overgrowth resulting in decreased passage of viable bacteria from
the gut lumen to MLNs and through IL-10-mediated inhibition of
intestinal inﬂammation, resulting in improvement of gut barrier
integrity and reduction of bacterial product translocation.
These ﬁndings highlight two important points. First, in clinical
practice, we challenge daily the utility of norﬂoxacin prophylaxis
in cirrhotic patients carrying quinolone-resistant bacteria or in
patients who had a previous SBP episode on norﬂoxacin. At this
time, we have no evidence that norﬂoxacin is ineffective in these
speciﬁc cases and the non-antibiotic effects of quinolone treat-
ment could be useful for these patients. Secondly, studying the
mechanism of action of quinolones on the immune system and
gut barrier could open areas of research aimed at the design of
new non-antibiotic therapeutic options. Non-antibiotic strategies
are clearly needed to limit the emergence of multi-resistant bac-
teria in a population susceptible to infections.Conﬂict interest
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